Yatin Suneja
Stock Analyst at Guggenheim
(2.41)
# 2,432
Out of 4,883 analysts
137
Total ratings
43.33%
Success rate
-0.39%
Average return
Main Sectors:
Stocks Rated by Yatin Suneja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Reiterates: Buy | $26 | $3.20 | +712.50% | 6 | Jun 25, 2025 | |
| ALMS Alumis | Reinstates: Buy | $18 | $3.31 | +443.81% | 2 | Jun 10, 2025 | |
| ANAB AnaptysBio | Maintains: Buy | $54 → $90 | $23.46 | +283.71% | 13 | May 28, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $23 → $25 | $1.49 | +1,577.85% | 5 | May 16, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,100 → $1,065 | $546.04 | +95.04% | 11 | May 9, 2025 | |
| GHRS GH Research | Maintains: Buy | $32 → $29 | $14.98 | +93.59% | 1 | May 9, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $155 → $165 | $127.88 | +29.03% | 5 | May 6, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $18 → $12 | $8.66 | +38.57% | 4 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $940 → $810 | $538.11 | +50.53% | 6 | May 1, 2025 | |
| ZURA Zura Bio | Reiterates: Buy | $15 | $1.11 | +1,251.35% | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $0.82 | +1,119.51% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $0.65 | +975.27% | 1 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $16.42 | - | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $84 | $18.17 | +362.30% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $9.86 | +356.39% | 3 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.90 | - | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $7.99 | - | 3 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $45 | $8.35 | +438.92% | 3 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $20.88 | -4.21% | 6 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.35 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $15.96 | - | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $65 | $15.30 | +324.84% | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $155 → $170 | $46.68 | +264.18% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.16 | - | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $7.95 | +528.93% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $90 | $20.95 | +329.70% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $125 | $107.50 | +16.28% | 8 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $16 | $10.74 | +48.98% | 2 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $77 | $47.50 | +62.11% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.90 | - | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $49 | $31.83 | +53.94% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $55 | $9.49 | +479.56% | 2 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $270 → $350 | $130.13 | +168.96% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.16 | - | 5 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.61 | - | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $13.81 | +73.79% | 1 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $91.20 | -62.72% | 2 | Jan 14, 2020 |
Larimar Therapeutics
Jun 25, 2025
Reiterates: Buy
Price Target: $26
Current: $3.20
Upside: +712.50%
Alumis
Jun 10, 2025
Reinstates: Buy
Price Target: $18
Current: $3.31
Upside: +443.81%
AnaptysBio
May 28, 2025
Maintains: Buy
Price Target: $54 → $90
Current: $23.46
Upside: +283.71%
Cabaletta Bio
May 16, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $1.49
Upside: +1,577.85%
argenx SE
May 9, 2025
Maintains: Buy
Price Target: $1,100 → $1,065
Current: $546.04
Upside: +95.04%
GH Research
May 9, 2025
Maintains: Buy
Price Target: $32 → $29
Current: $14.98
Upside: +93.59%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $155 → $165
Current: $127.88
Upside: +29.03%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $18 → $12
Current: $8.66
Upside: +38.57%
Regeneron Pharmaceuticals
May 1, 2025
Maintains: Buy
Price Target: $940 → $810
Current: $538.11
Upside: +50.53%
Zura Bio
Mar 26, 2025
Reiterates: Buy
Price Target: $15
Current: $1.11
Upside: +1,251.35%
Mar 26, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $0.82
Upside: +1,119.51%
Mar 21, 2025
Reiterates: Buy
Price Target: $7
Current: $0.65
Upside: +975.27%
Mar 20, 2025
Reiterates: Buy
Price Target: n/a
Current: $16.42
Upside: -
Mar 12, 2025
Reiterates: Buy
Price Target: $84
Current: $18.17
Upside: +362.30%
Mar 12, 2025
Reiterates: Buy
Price Target: $45
Current: $9.86
Upside: +356.39%
Mar 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.90
Upside: -
Jan 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $7.99
Upside: -
Jan 3, 2025
Upgrades: Buy
Price Target: $45
Current: $8.35
Upside: +438.92%
Jan 3, 2025
Downgrades: Neutral
Price Target: $20
Current: $20.88
Upside: -4.21%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $15.96
Upside: -
Oct 25, 2024
Maintains: Buy
Price Target: $50 → $65
Current: $15.30
Upside: +324.84%
Aug 14, 2024
Maintains: Buy
Price Target: $155 → $170
Current: $46.68
Upside: +264.18%
May 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.16
Upside: -
Apr 29, 2024
Initiates: Buy
Price Target: $50
Current: $7.95
Upside: +528.93%
Feb 27, 2024
Maintains: Buy
Price Target: $72 → $90
Current: $20.95
Upside: +329.70%
Feb 21, 2024
Maintains: Buy
Price Target: $110 → $125
Current: $107.50
Upside: +16.28%
Nov 15, 2023
Maintains: Buy
Price Target: $17 → $16
Current: $10.74
Upside: +48.98%
Nov 15, 2023
Maintains: Buy
Price Target: $70 → $77
Current: $47.50
Upside: +62.11%
Jul 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.90
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $49
Current: $31.83
Upside: +53.94%
May 18, 2023
Maintains: Buy
Price Target: $52 → $55
Current: $9.49
Upside: +479.56%
May 1, 2023
Upgrades: Buy
Price Target: $270 → $350
Current: $130.13
Upside: +168.96%
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $9.16
Upside: -
Oct 14, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.61
Upside: -
May 31, 2022
Initiates: Buy
Price Target: $24
Current: $13.81
Upside: +73.79%
Jan 14, 2020
Maintains: Buy
Price Target: $29 → $34
Current: $91.20
Upside: -62.72%